Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoterCilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: towards pharmacogenetics.Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.Update on the therapeutic potential of PDE4 inhibitors.Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.ABCD of the phosphodiesterase family: interaction and differential activity in COPDUpdate on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Novel therapies for the treatment of inflammatory airway disease.Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipramChronic obstructive pulmonary disease . 7: Management of COPDAdvances in the management of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease * 12: New treatments for COPDAn update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease.Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolPharmacotherapy of asthma.Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control.Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokinesMinimal clinically important differences in COPD lung function.Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy.Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation.Pharmacological treatment of chronic obstructive pulmonary disease.Biological targets for therapeutic interventions in COPD: clinical potentialTreating COPD with PDE 4 inhibitors.Is 'GOLD' standard for the management of COPD in clinical practice?DISC1 as a therapeutic target for mental illnesses.PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain.Protease inhibitors in respiratory disease: focus on asthma and chronic obstructive pulmonary disease.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
P2860
Q24202545-B6784571-D425-443B-B200-465D07EEF592Q24234493-F8B5D247-95FE-4D16-A591-7590A99DD034Q24301633-592C1BE6-D401-41D4-B39E-868DE0632FBDQ33258089-B46C766D-B58A-41CD-9CC0-15EAAB0BB95DQ33600138-1567F588-7CBB-4A12-81B8-B0DF83478331Q33721181-058D73D2-8DD1-4ED3-A629-4D55281F89E8Q34107488-9B145330-BFDA-42FF-9558-B942B2AD9380Q34155193-70489717-5665-4235-A7D6-1AA6ADE49754Q34961511-83F4C386-7554-4798-8A07-6CB67AB6DB44Q35028812-087ECD4A-C3CD-4256-8778-586C30E4310FQ35040779-CB057206-E992-4034-A22C-E9D288A5077DQ35045854-B27299B1-4B33-439C-89E6-CE1842004451Q35075588-EB7F6B5D-FC45-435E-8C5E-08DF6AC9E1DCQ35164693-D12A3F21-C05E-4E26-B94E-79863BF307AAQ35208742-88F8C642-921A-4205-9034-6E0ED62D3898Q35827644-ACBDBEE8-7A08-411B-B0A8-36F5598D9664Q35842492-6B4F09BC-61F1-43C6-8962-36296F803674Q36086153-5F38EA0C-10C3-4127-9016-11271EE49C56Q36119936-5627DECA-713A-430C-B032-6C2832CD2CF1Q36165890-9C9E0CE2-6142-4F2A-9A71-4CCB6B314B64Q36183282-46CE6282-54B2-4B1B-96D6-52C13201DA63Q36376519-85A5A7A5-42A1-4371-BD98-F088213CEAAAQ36443665-F0B38F34-F074-43D8-BCF3-5DB5FD00BD70Q36554689-90599E39-D5FE-4D79-AC61-1803D6A8194EQ36648886-018A36AE-737E-419B-AFE3-71A68E1BA111Q36669438-4B0BAE22-B41A-48F4-B7C0-10E1A84D0698Q36677411-F3E7987D-03BF-40D8-B754-2EF7279E6BB7Q36792648-73BBD90B-33C2-41EE-866A-9655EDDA1CCFQ36861614-7EA1FE9E-D183-4AA4-8AD8-4C928277CFC4Q36964706-13E92B27-5395-4D0E-B23F-4860B0C21422Q37017344-82F6104C-9247-4CB0-82F0-AC70E303B6AAQ37018843-7E9F45D8-7113-406A-8C0F-4CD8A58F2733Q37082594-87268A96-3C16-47E6-B5B3-9A7524319AB8Q37450159-FD3C6909-6ACD-4043-AD69-E2B227FC28E2Q37698116-16D9530D-8E1A-4C9B-91AC-53E215380A23Q37963175-D45F56A5-B0CC-466B-8070-7B66937E5BD9Q38681962-9B40C66D-6065-4DF9-ACEE-E214F08B9623Q40054002-47F3ADD7-FA93-437F-A597-7FCC59CB2138Q43061558-5075F844-7B2D-458E-9E6A-4CAC5764E1B1Q43061572-B2249F6C-7EF8-4ADA-B444-D742AA90DB2D
P2860
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@en
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@nl
type
label
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@en
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@nl
prefLabel
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@en
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@nl
P2093
P1433
P1476
Cilomilast, a selective phosph ...... andomised, dose-ranging study.
@en
P2093
C Brambilla
C H Compton
G Schultze-Werninghaus
International Study Group
J P Creemers
N C Barnes
P304
P356
10.1016/S0140-6736(01)05481-2
P407
P577
2001-07-01T00:00:00Z